biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Reasons Why Pharmas May Have Avoided Bioasis

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jun 21, 2023 7:14pm

124 Views

Post# 35508140

RE:RE:RE:Reasons Why Pharmas May Have Avoided Bioasis

Would Rathjen ever want to sell Bioasis to a larger pharma? A larger pharma would never allow her to profit from such a sale as she would have with Biodexa, and especially with a private company if she followed xB3 to that secret place.

Besides, Bioasis never proved xB3 was capable and valuable. For reason I posted earlier, I don't think a large pharma would touch Bioasis with a 12 foot hypodermic.

jd

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments